First Western Trust Bank Sells 243 Shares of Eli Lilly and Company (NYSE:LLY)

First Western Trust Bank lessened its stake in Eli Lilly and Company (NYSE:LLY) by 11.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,798 shares of the company’s stock after selling 243 shares during the quarter. First Western Trust Bank’s holdings in Eli Lilly and Company were worth $843,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Silicon Valley Capital Partners bought a new stake in Eli Lilly and Company during the 1st quarter valued at $25,000. Laffer Tengler Investments bought a new stake in Eli Lilly and Company during the 1st quarter valued at $33,000. Raleigh Capital Management Inc. raised its holdings in Eli Lilly and Company by 156.4% during the 1st quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock valued at $34,000 after acquiring an additional 61 shares during the period. Activest Wealth Management bought a new stake in Eli Lilly and Company during the 2nd quarter valued at $40,000. Finally, Riggs Asset Managment Co. Inc. raised its holdings in Eli Lilly and Company by 50.4% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 179 shares of the company’s stock valued at $61,000 after acquiring an additional 60 shares during the period. Institutional investors own 81.38% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 670 shares of the firm’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $571.10, for a total value of $382,637.00. Following the completion of the sale, the chief accounting officer now directly owns 4,708 shares in the company, valued at $2,688,738.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 215,000 shares of the firm’s stock in a transaction dated Wednesday, October 11th. The shares were sold at an average price of $605.44, for a total value of $130,169,600.00. Following the completion of the sale, the insider now directly owns 99,768,810 shares in the company, valued at $60,404,028,326.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Donald A. Zakrowski sold 670 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $571.10, for a total transaction of $382,637.00. Following the completion of the sale, the chief accounting officer now owns 4,708 shares of the company’s stock, valued at $2,688,738.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 535,538 shares of company stock worth $20,881,299,452. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Wednesday, November 8th. Jefferies Financial Group upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their price target for the company from $408.00 to $615.00 in a research report on Tuesday, August 8th. Truist Financial increased their price objective on Eli Lilly and Company from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Bank of America increased their price objective on Eli Lilly and Company from $600.00 to $700.00 in a research report on Friday, October 6th. Finally, UBS Group reiterated a “buy” rating and issued a $710.00 price objective (up previously from $612.00) on shares of Eli Lilly and Company in a research report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twenty have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $557.00.

Eli Lilly and Company Trading Up 0.9 %

Shares of Eli Lilly and Company stock traded up $5.51 during trading on Monday, reaching $597.22. 1,494,823 shares of the stock were exchanged, compared to its average volume of 3,097,466. The company has a quick ratio of 0.82, a current ratio of 1.05 and a debt-to-equity ratio of 1.59. The stock’s fifty day moving average is $577.98 and its 200 day moving average is $509.95. The firm has a market cap of $566.95 billion, a price-to-earnings ratio of 107.54, a price-to-earnings-growth ratio of 3.57 and a beta of 0.33. Eli Lilly and Company has a 1 year low of $309.20 and a 1 year high of $629.97.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be issued a dividend of $1.13 per share. The ex-dividend date is Tuesday, November 14th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.76%. Eli Lilly and Company’s dividend payout ratio is currently 81.88%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.